Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

By LabMedica International staff writers
Posted on 20 Apr 2014
Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating MCF-10F human normal breast epithelial cells with a high dose of estradiol. More...
The model system consisted of four distinct cell lines which demonstrated a progressive neoplastic transformation: MCF-10F, normal stage; trMCF, transformed MCF-10F; bsMCF, invasive stage; and caMCF, tumorigenic stage. In three-dimensional cultures, MCF-10F cells formed tubules resembling the structures in the normal mammary gland. After treatment with estradiol, these cells formed tubules and spherical masses which were indicative of transformation.

In the current study the investigators evaluated the effect of all trans-retinoic acid (ATRA) at different stages of neoplastic transformation. Retinoids have been used as potential chemotherapeutic or chemopreventive agents because of their differentiative, antiproliferative, proapoptotic, and antioxidant properties.

Cells that only formed spherical masses in collagen were isolated (trMCF clone 11) and treated with ATRA. After treatment with a concentration of one micromolar ATRA, the trMCF clone 11 cells showed tubules in collagen. Gene expression studies showed that 207 genes upregulated in transformed trMCF clone 11 cells were downregulated after one micromolar ATRA treatment to levels comparable to those found in the normal breast epithelial cells MCF-10F. Furthermore, 236 genes that were downregulated in trMCF clone 11 were upregulated after one micromolar ATRA treatment to similar levels shown in normal epithelial cells. These 443 genes defined a signature of the ATRA reprogramming effect.

Results published in the March 21, 2014, edition of the International Journal of Oncology showed that one micromolar ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process and antagonistically regulate breast cancer associated genes. On the other hand, the invasive and tumorigenic cells did not show any changes in morphology after ATRA treatment.

“It looks like retinoic acid exerts effects on cancer cells in part via the modulation of the epigenome,” said senior author Dr. Sandra V. Fernandez, assistant research professor of medical oncology at Thomas Jefferson University. “We were able to see this effect of retinoic acid because we were looking at four distinct stages of breast cancer. It will be interesting to see if these results can be applied to patients.”

Related Links:

Thomas Jefferson University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Portable POCT Blood Gas Analyzer
BD100
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.